William Blair analyst Andy Hsieh has maintained their bullish stance on CRDF stock, giving a Buy rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Andy Hsieh has given his Buy rating due to a combination of factors surrounding Cardiff Oncology’s promising developments. The company has recently completed enrollment for its Phase II CRDF-004 study of onvansertib, targeting RAS mutation-positive metastatic colorectal cancer (mCRC). This progress is seen as a strategic move that could potentially transform treatment paradigms for this type of cancer.
Hsieh believes that Cardiff Oncology is at a pivotal moment, as the de-risking of onvansertib makes it a compelling investment opportunity. The drug’s potential to extend its application beyond colorectal cancer to other types such as pancreatic, small-cell lung, and breast cancers, further supports this optimistic outlook. These factors contribute to Cardiff Oncology being one of the top ideas in their coverage universe, reinforcing the Buy rating.